Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hepatitis d study hunts for biomarkers to predict liver damage

NCT ID NCT06160635

Knowledge-focused Sponsor: Hannover Medical School Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 01, 2026 · Last updated Oct 02, 2026 · Updated 1 time

Summary

Hepatitis D is the most severe form of viral hepatitis, often leading to liver failure and death. Researchers at Hannover Medical School are running a multicenter cohort study to screen blood and liver samples from 750 adults with hepatitis D for biomarkers linked to disease control, progression, and treatment response. The study uses multiomics approaches to analyze genes, proteins, metabolites, and immune cells, aiming to personalize surveillance and antiviral treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers find reliable biomarkers, doctors could one day tailor hepatitis D monitoring and treatment to each person, potentially reducing liver failure and improving quality of life.
What could go wrong
This is an observational cohort study, so it cannot prove that any biomarker causes or predicts outcomes. Findings may not apply to all hepatitis D patients, and any clinical benefit is likely years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All adult patients chronically infected with the hepatitis D virus (anti-HDV positive) can be included. For cohort B historical liver biopsies need to be available.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Anti-HDV positive * ≥18 years old * Sex: m/f/d * Informed consent for prospective procedures Exclusion Criteria: * Anti-HDV negative

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic liver disease HDV HDV infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (University of Milan)

    NOT_YET_RECRUITING

    Milan, Italy

  • Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology

    RECRUITING

    Hanover, 30625, Germany

  • Institutul de Boli Infectioase "Prof. Dr. Matei Bals"

    RECRUITING

    Bucharest, 021105, Romania

  • Karolinska University Hospital and Karolinska Institutet

    RECRUITING

    Stockholm, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.